Reveal Genomics
Business Services · Spain · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Carrer De Villarroel 170 Planta 5, Barce...Website
www.reveal-genomics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Reveal Genomics
REVEAL GENOMICS specializes in precision oncology by developing advanced genomic tests that leverage comprehensive genetic and clinical data of patients. Their flagship product, HER2DX, is designed to assist healthcare professionals in selecting optimal treatment strategies for patients with HER2-positive breast cancer. The company aims to transform the use of biomarkers in oncology through innovative, easy-to-interpret testing solutions. Targeting healthcare professionals, REVEAL GENOMICS is committed to enhancing patient care with high-quality genomic analysis.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Reveal Genomics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Reveal Genomics had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Reveal Genomics is spiking on competitors!
Funding: Get notified immidiatlly once Reveal Genomics has new funding data
Website visits: Recent activity has been detected on your website
Reveal Genomics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Reveal Genomics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Reveal Genomics recently announced quarterly report
Product Launch: Get notified when Reveal Genomics launches new products
Congratulate Masked Content for being promoted to Masked Content at Reveal Genomics
Recommended Actions
Reach out to Masked Content who joined Reveal Genomics as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Reveal Genomics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Reveal Genomics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Reveal Genomics.
Reveal Genomics Tech Stack
A closer look at the technologies used by Reveal Genomics
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Executive Move
Executive Moves, Board of Directors
New Hire
Executive Move
Executive Moves, New Hire
Award
Award
Reveal Genomics News & Media
ASCO 2025: REVEAL GENOMICS Unveils New HER2DX Data From 800+ Patients
BARCELONA, Spain--(BUSINESS WIRE)--REVEAL GENOMICS, S.L., a biotechnology company advancing precision oncology through biomarker innovation, today announced the presentation of four independent studies at the 2025 ASCO Annual Meeting. The studies, involving more than 800 patients, evaluated the clinical utility of its flagship test, HER2DX, in early-stage HER2-positive (HER2+) breast cancer. The four studies, CompassHER2 pCR, BionHER, RESPECT and DFCI, validate HER2DX as a powerful genomic toolREVEAL GENOMICS and Ona Therapeutics Join Forces to Advance Next-generation Cancer Treatment
BARCELONA, Spain--(BUSINESS WIRE)--REVEAL GENOMICS and Ona Therapeutics today announced a strategic collaboration aimed at accelerating the clinical development of ONA-255, a next-generation ADC designed to enhance the precision and efficacy of cancer treatment across multiple tumor types. ONA-255 is positioned to be a first-in-class molecule against a novel ADC target present in multiple, prevalent solid tumor types. Ona has privileged insight of the target as a hallmark of molecular adaptatioGroundbreaking Study Confirms Clinical Decision Impact of HER2DX® Genomic Assay in Early-Stage HER2-Positive Breast Cancer
BARCELONA, Spain--(BUSINESS WIRE)--REVEAL GENOMICS®, a pioneering Barcelona-based biotech company dedicated to advancing precision oncology, is proud to announce the publication of a groundbreaking study demonstrating the clinical impact of HER2DX®, its genomic diagnostic test designed for early-stage HER2-positive (HER2+) breast cancer. The study, now published in ESMO Real World Data and Digital Oncology, is the first prospective real-world investigation assessing the impact of HER2DX® resultREVEAL GENOMICS® Links Immune Tumor Response to Longevity in Breast Cancer Survivors
BARCELONA, Spain--(BUSINESS WIRE)--REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker innovation, has unveiled groundbreaking research that highlights a significant, previously unrecognized link between an anti-tumor adaptive immune response and improved survival outcomes in individuals who have apparently overcome breast cancer. This study highlights the clinical value of REVEAL GENOMICS®' immune gene combinations, whic
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Reveal Genomics
Sign Up For FreeTo access detailed company insights
REVEAL GENOMICS specializes in precision oncology by developing advanced genomic tests that leverage comprehensive genetic and clinical data of patients. Their flagship product, HER2DX, is designed to assist healthcare professionals in selecting optimal treatment strategies for patients with HER2-positive breast cancer. The company aims to transfor... Read More
